Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
27.60
+0.27 (0.99%)
Apr 8, 2026, 11:17 AM EDT - Market open
AAPG Revenue
In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M CNY, down -41.46%. Ascentage Pharma Group International had revenue of 340.42M in the half year ending December 31, 2025, with 329.37% growth.
Revenue (ttm)
574.12M CNY
Revenue Growth
-41.46%
P/S Ratio
29.21
Revenue / Employee
748,527 CNY
Employees
767
Market Cap
2.40B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Zai Lab | 460.16M |
| Adaptive Biotechnologies | 276.98M |
| Beam Therapeutics | 139.74M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
AAPG News
- 11 days ago - Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript - GuruFocus
- 13 days ago - Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewsWire
- 21 days ago - Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Group International is Now Oversold (AAPG) - Nasdaq
- 2 months ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 2 months ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga